October 24, 2017 / 12:24 PM / in a month

BRIEF-Myriad submits BRACAnalysis® CDx application for regulatory approval in Japan

Oct 24 (Reuters) - Myriad Genetics Inc

* Myriad submits BRACAnalysis® CDX application for regulatory approval in Japan for HER2- metastatic breast cancer

* Myriad Genetics Inc - submitted BRACAnalysis CDX in Japan for review by PMDA and marketing approval by Ministry Of Health, Labor and Welfare​

* Myriad Genetics Inc - ‍submitted marketing approval as a companion diagnostic to olaparib for use in HER2- metastatic breast cancer patients​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below